

PRONOMZ VENTURES LLP

Regd. Office: Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 | Fax: +91 80 4657 0400 | E-mail: info@agnus.in | www.agnus.in | LLPIN: AAA-3757

28 September 2020

To

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street.

Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex,

Bandra (E), Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Ms. Manjula Ramamurthy Company Secretary & Compliance Officer Strides Pharma Science Ltd 201, Devavrata, Sector 17, Vashi, Navi Mumbai- 400703.

Dear Sir/ Madam,

Sub: Disclosure under Regulation 29 (2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Promoter Entities

Please find enclosed herewith the disclosure under regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition of shares of Strides Pharma Science Ltd is being done inter-se among promoters in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 and there is no change in promoter holding consequent to such transfer. The disclosure is being made on behalf of the promoter group.

We request you to take the same on record.

Kindly take the same on record.

Thanking you, Yours faithfully,

For and on behalf of M/s Pronomz Ventures LLP

Promoter Group Entity of Strides Pharma Science Ltd

Kannan P R
Designated Partner

Encl.: A/a



PRONOMZ VENTURES LLP

Regd. Office: Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 | Fax: +91 80 4657 0400 | E-mail: info@agnus.in | www.agnus.in | LLPIN: AAA-3757

<u>Disclosures under Regulation 29(2) of SEBI</u> (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Strides Pharma Scie			
Name of the seller		Pronomz Ventures LLP		
Whether the acquirer belongs to Promoter/Promoter Group	Yes			
Name of the stock exchange where shares of the TC are listed	BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE')			
Details of Acquisition / disposal is as follows	- Number	% w.r.t total share/voting capital wherever applicable (*)	% w.r.t total diluted share/voting capital of TC (**)	
Before the acquisition/disposal undeconsideration of:	er			
a) Shares carrying voting rights b) Shares in nature of encumbrance	1,26,65,000 re	14.13%	14.13%	
(pledge/lien/non-disposal undertaking/ others)c) Voting Rights (VR) otherwise than b	ov l	-	~:	
shares d) Warrants/convertibles securities /ar	- 2		=	
other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding)	ne l	п.	•	
in each category) e) Total (a +b +c+ d)	1,26,65,000	14.13%	14.13%	
Details of acquisition/sale:				
a) Shares carrying voting rightsb) Voting Rights (VR) otherwise than k shares	33,12,500 ey	3.70%	3.70% -	
 c) Warrants/convertibles securities /ar other instrument that entitles th acquirer to receive shares carryir voting rights in the TC (specify holdir in each category) 	ne ng	-	π.	
d) Shares encumbered invoked/released by the acquirer e) Total (a +b +c +/- d)	33,12,500	3.70%	3.70%	
\				



PRONOMZ VENTURES LLP

Regd. Office: Plot No. 30, 'Galaxy', 1st Main Road, J. P. Nagar Third Phase, Bengaluru - 560 078, Karnataka. India Tel.: +91 80 4657 0300 | Fax: +91 80 4657 0400 | E-mail: info@agnus.in | www.agnus.in | LLPIN: AAA-3757

After the acquisition/sale, holding of:				
a) Shares carrying voting rights	1,59,77,500	17.83%	17.83%	
b) Shares encumbered with the acquirerc) VR otherwise than by shares		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		
d) Warrants/convertibles securities /any		:: ::=:	; * :	
other instrument that entitles the				
acquirer to receive shares carrying	-	H=1	:=:	
voting rights in the TC (specify holding				
in each category)	1,59,77,500	17.83%	17.83%	
e) Total (a +b +c+ d)	1,53,77,500	17.83%	17.83%	
Mode of acquisition /sale (eg open market/off-	Inter-se Transfer between promoters			
market/ public issue/ preferential allotment /				
inter-se transfer, etc)				
Date of acquisition /sale of shares /VR or date	25 th September 2020			
of receipt intimation of allotment shares,				
whichever applicable				
Equity share capital /total voting capital of the	896,256,640 comprising of of 89,625,664 equity shares of INR			
TC before the said acquisition /sale	10 each			
Equity share capital /total voting capital of the	896,256,640 comprising of 89,625,664 equity shares of INR 10			
TC after the said acquisition /sale	each			
Total Diluted share/ voting capital of the TC	896,256,640 comprising of 89,625,664 equity shares of INR 10			
after the said acquisitions	each			

- (*) Total Share capital to be taken as per the latest filing done by the company to the stock exchange under clause 35 of the listing Agreement
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertibles securities/warrants into equity shares of the TC.

For and on behalf of M/s Pronomz Ventures LLP

Promoter Group Entity of Strides Pharma Science Ltd

Kannan P R Designated Partner

Place: Bengaluru

Date: 28 September 2020

Arun Kumar Family Office increase its holding in Strides by 4.37%

Purchases 3.31 million shares from SeQuent and 600,000 shares from Shasun family

The family office of Arun Kumar, founder and non-executive Chairman of Strides Pharma Science Limited ("Strides" or "Company") would like to update that it has completed the purchase of 3.31 million shares (3.70% of Total Outstanding Shares) of Strides held by SeQuent Scientific Limited ("SeQuent") for an aggregate consideration of ₹1,573 million. The transaction was duly approved by the Shareholders of SeQuent on Sep 19, 2020.

Further, on Sep 11, 2020, the Family Office of Arun Kumar also purchased 600,000 shares (0.67% of the total outstanding shares) of Strides from the Shasun family who are also promoters in the Company.

The information has been shared with the Company and its stakeholders for prudent disclosures.